Abstract:
Background: Although a safe and efective vaccine is available, measles remains an important cause of mortality
and morbidity among young children in Sub-Saharan Africa (SSA). The WHO and UNICEF recommended measles containing vaccine dose 2 (MCV2) in addition to measles-containing vaccine dose 1 (MCV1) through routine services
strategies. Many factors could contribute to the routine dose of MCV2 coverage remaining far below targets in many
countries of this region. This study aimed to assess the prevalence of MCV2 utilization among children aged 24–35
months and analyze factors associated with it by using recent nationally representative surveys of SSA countries.
Methods: Secondary data analysis was done based on recent Demographic and Health Surveys (DHS) data from
eight Sub-Saharan African countries. In this region, only eight countries have a record of routine doses of measles containing vaccine dose 2 in their DHS dataset. The multilevel binary logistic regression model was ftted to identify
signifcantly associated factors. Variables were extracted from each of the eight country’s KR fles. Adjusted Odds
Ratios (AOR) with a 95% Confdence Interval (CI) and p-value≤0.05 in the multivariable model were used to declare
signifcant factors associated with measles-containing vaccine dose 2 utilization.
Result: The pooled prevalence of MCV2 utilization in SSA was 44.77% (95% CI: 27.10–62.43%). In the multilevel analy sis, mothers aged 25–34 years [AOR=1.15,95% CI (1.05–1.26), mothers aged 35 years and above [AOR=1.26, 95% CI
(1.14–1.41)], maternal secondary education and above [AOR=1.27, 95% CI (1.13–1.43)], not big problem to access
health facilities [AOR=1.21, 95% CI (1.12–1.31)], four and above ANC visit [AOR=2.75, 95% CI (2.35–3.24)], PNC visit
[AOR=1.13, 95% CI (1.04–1.23)], health facility delivery [AOR=2.24, 95% CI (2.04–2.46)], were positively associated
with MCV2 utilization. In contrast, multiple twin [AOR=0.70, 95% CI (0.53–0.95)], rural residence [AOR=0.69, 95% CI
(0.57–0.82)] and high community poverty [AOR=0.66, 95% CI (0.54–0.80)] were found to be negatively associated
with MCV2 utilization.
